Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Xeris Pharmaceuticals stock price, quote, forecast and news

XERS
US98422L1070
A2JPE9

Price

2.51
Today +/-
-0.02
Today %
-0.79 %
P

Xeris Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Xeris Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Xeris Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Xeris Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Xeris Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Xeris Pharmaceuticals Stock Price History

DateXeris Pharmaceuticals Price
9/6/20242.51 undefined
9/5/20242.53 undefined
9/4/20242.64 undefined
9/3/20242.59 undefined
8/30/20242.81 undefined
8/29/20242.80 undefined
8/28/20242.79 undefined
8/27/20242.88 undefined
8/26/20242.90 undefined
8/23/20242.88 undefined
8/22/20242.80 undefined
8/21/20242.84 undefined
8/20/20242.70 undefined
8/19/20242.72 undefined
8/16/20242.69 undefined
8/15/20242.62 undefined
8/14/20242.55 undefined
8/13/20242.54 undefined
8/12/20242.25 undefined

Xeris Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Xeris Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Xeris Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Xeris Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Xeris Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Xeris Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Xeris Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Xeris Pharmaceuticals’s growth potential.

Xeris Pharmaceuticals Revenue, EBIT and net profit per share

DateXeris Pharmaceuticals RevenueXeris Pharmaceuticals EBITXeris Pharmaceuticals Net Income
2029e398.49 M undefined0 undefined148.94 M undefined
2028e364.08 M undefined101.83 M undefined80.55 M undefined
2027e314.21 M undefined70.66 M undefined48.25 M undefined
2026e272.76 M undefined38.49 M undefined9.73 M undefined
2025e229.11 M undefined-7.23 M undefined-37.74 M undefined
2024e197.27 M undefined-33.82 M undefined-60.54 M undefined
2023163.91 M undefined-44.01 M undefined-62.26 M undefined
2022110.2 M undefined-71.8 M undefined-94.7 M undefined
202149.6 M undefined-106.5 M undefined-122.7 M undefined
202020.4 M undefined-83.6 M undefined-91.1 M undefined
20192.7 M undefined-122.4 M undefined-125.6 M undefined
20182.5 M undefined-59.3 M undefined-60.1 M undefined
20171.6 M undefined-26.6 M undefined-26.6 M undefined
20161.1 M undefined-13.2 M undefined-13.2 M undefined

Xeris Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
11222049110163197229272314364398
--100.00-900.00145.00124.4948.1820.8616.2418.7815.4415.929.34
100.00100.00100.0050.0055.0073.4779.0982.82------
1121113687135000000
-13-26-59-122-83-106-71-44-33-738701010
-1,300.00-2,600.00-2,950.00-6,100.00-415.00-216.33-64.55-26.99-16.75-3.0613.9722.2927.75-
-13-26-60-125-91-122-94-62-60-3794880148
-100.00130.77108.33-27.2034.07-22.95-34.04-3.23-38.33-124.32433.3366.6785.00
19.719.720.826.142.679135.6137.67000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Xeris Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Xeris Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
32.342112.675.5133.8102.412272.45
0.11.22.95.66.917.530.839.2
00000000
0002.28.418.124.738.84
0.80.82.44.13.24.69.35.78
33.244117.987.4152.3142.6186.8156.26
0.30.827.96.76.69.529.18
00013.20000
00000000
00000131.5120.6109.76
0000022.922.922.86
00.20.10.40.20.84.74.54
0.312.121.56.9161.8157.7166.34
33.545120108.9159.2304.4344.5322.6
               
62.997.9000000.01
2.12.8196.1260.6371.1555.4600610.25
-34-60.6-120.7-246.2-337.4-460.1-554.8-617.03
00-0.10000-0.03
00000000
3140.175.314.433.795.345.2-6.78
1.320.95.63.18.94.611.57
0.92.68.221.524.868.166.463.35
0.30.31.10.30.322.720.28
00000000
00000000
2.54.910.227.428.27973.795.19
0031.958.38788.1187.1190.93
000004.93.52.27
00.12.68.910.237.135.140.99
00.134.567.297.2130.1225.7234.19
2.5544.794.6125.4209.1299.4329.38
33.545.1120109159.1304.4344.6322.6
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Xeris Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Xeris Pharmaceuticals's financial health and stability.

Assets

Xeris Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Xeris Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Xeris Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Xeris Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-13-26-60-125-91-122-94-62
0001111212
000000-1-1
-31111-211-35-6
1131420242821
0013471027
00000000
-16-24-56-104-80-95-102-47
00-1-10-10-2
00-68-2-279734-6
00-66-1-279934-3
00000000
0035256901010
335102626627300
3351288012627127-1
---9.00-6.00-10.00--4.00-1.00
00000000
-1293-26182959-54
-16.13-25.36-57.79-105.46-80.94-96.63-103.41-49.29
00000000

Xeris Pharmaceuticals stock margins

The Xeris Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Xeris Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Xeris Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Xeris Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Xeris Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Xeris Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Xeris Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Xeris Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Xeris Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Xeris Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Xeris Pharmaceuticals Margin History

Xeris Pharmaceuticals Gross marginXeris Pharmaceuticals Profit marginXeris Pharmaceuticals EBIT marginXeris Pharmaceuticals Profit margin
2029e82.52 %0 %37.38 %
2028e82.52 %27.97 %22.12 %
2027e82.52 %22.49 %15.36 %
2026e82.52 %14.11 %3.57 %
2025e82.52 %-3.16 %-16.47 %
2024e82.52 %-17.15 %-30.69 %
202382.52 %-26.85 %-37.98 %
202279.49 %-65.15 %-85.93 %
202173.19 %-214.72 %-247.38 %
202054.41 %-409.8 %-446.57 %
201940.74 %-4,533.33 %-4,651.85 %
201896 %-2,372 %-2,404 %
2017100 %-1,662.5 %-1,662.5 %
2016100 %-1,200 %-1,200 %

Xeris Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Xeris Pharmaceuticals earnings per share therefore indicates how much revenue Xeris Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Xeris Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Xeris Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Xeris Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Xeris Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Xeris Pharmaceuticals Revenue, EBIT and net profit per share

DateXeris Pharmaceuticals Sales per ShareXeris Pharmaceuticals EBIT per shareXeris Pharmaceuticals Earnings per Share
2029e2.67 undefined0 undefined1 undefined
2028e2.44 undefined0 undefined0.54 undefined
2027e2.11 undefined0 undefined0.32 undefined
2026e1.83 undefined0 undefined0.07 undefined
2025e1.54 undefined0 undefined-0.25 undefined
2024e1.32 undefined0 undefined-0.41 undefined
20231.19 undefined-0.32 undefined-0.45 undefined
20220.81 undefined-0.53 undefined-0.7 undefined
20210.63 undefined-1.35 undefined-1.55 undefined
20200.48 undefined-1.96 undefined-2.14 undefined
20190.1 undefined-4.69 undefined-4.81 undefined
20180.12 undefined-2.85 undefined-2.89 undefined
20170.08 undefined-1.35 undefined-1.35 undefined
20160.06 undefined-0.67 undefined-0.67 undefined

Xeris Pharmaceuticals business model

Xeris Pharmaceuticals Inc is a US pharmaceutical company that was founded in 2005. The company is headquartered in Chicago and is listed on the Nasdaq stock exchange. The business model of Xeris Pharmaceuticals is focused on providing patients and medical professionals with a wide range of products and services that improve patients' lives while promoting the development of effective and safe drugs. Xeris Pharmaceuticals focuses on the development of drugs made from peptides and proteins. The aim is to provide innovative drugs to patients with rare diseases or unmet therapeutic needs. Over the years, Xeris Pharmaceuticals has diversified into various sectors. One of the most important sectors is the diabetes industry. In this area, the company offers the Gvoke product family, a lightweight auto-injection method designed for adults, adolescents, and children with type 1 diabetes, as well as adults with type 2 diabetes. The Gvoke product is intended for patients with severe hypoglycemia and provides a quick and easy way to treat life-threatening hypoglycemic episodes. Another important sector for Xeris Pharmaceuticals is the neurology industry. In this area, the company has developed an injection device called XeriSol, specifically designed for the treatment of epilepsy or neurological seizures. The active ingredient used is diazepam, which has a rapid and reliable effect on seizures. Xeris Pharmaceuticals is also involved in cancer treatment. The company has developed a pituitary hormone analog called Pasireotide, which is used to treat Cushing's disease, a rare condition caused by hormone overproduction. The drug fits well into Xeris Pharmaceuticals' business model as it is peptide-based and offers better efficacy and safety than other drugs in this area. Overall, Xeris Pharmaceuticals has a strong pipeline of drugs that offer the company great potential for future growth. The development of innovative drugs and drug combinations is an important strategy for Xeris Pharmaceuticals to help patients with rare diseases or unmet therapeutic needs. In this regard, Xeris Pharmaceuticals has also formed partnerships with other leading pharmaceutical companies such as Sanofi, Eli Lilly, and Roche. These partnerships allow the company to accelerate its drug development and offer its products in the international market. In conclusion, the success story of Xeris Pharmaceuticals shows that the company is an important player in the pharmaceutical industry and plays a crucial role in the development of innovative, safe, and effective drugs for patients with rare diseases and unmet therapeutic needs. With its wide range of products, partnerships, and strong pipeline of innovative drugs, Xeris Pharmaceuticals is a company that has great potential for successful growth in the future. Xeris Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Xeris Pharmaceuticals SWOT Analysis

Strengths

Xeris Pharmaceuticals Inc has several key strengths that contribute to its success:

  • Strong product portfolio: Xeris Pharmaceuticals offers a range of innovative drugs, providing diverse revenue streams and reducing dependency on a single product.
  • Advanced technology: The company's proprietary formulation technology enables the development of stable, ready-to-use injectable drugs with extended stability and improved patient convenience.
  • Strategic partnerships: Xeris Pharmaceuticals has formed strategic alliances with leading pharmaceutical companies, enhancing its market presence and access to distribution channels.
  • Experienced team: The company boasts a dedicated team of experts with extensive experience in the pharmaceutical industry, contributing to efficient drug development and commercialization processes.

Weaknesses

Despite its strengths, Xeris Pharmaceuticals Inc also faces certain weaknesses that need to be addressed:

  • Reliance on limited product pipeline: The company's success heavily relies on the success of its current product portfolio, making it vulnerable to market fluctuations and competition.
  • Market entry barriers: The pharmaceutical industry is highly regulated, posing challenges for the development and approval process of new drugs. This may hinder Xeris Pharmaceuticals' ability to bring new products to market quickly.
  • Financial constraints: Xeris Pharmaceuticals may face financial limitations for research and development activities, hindering the introduction of new drugs into the market and potentially affecting its growth prospects.

Opportunities

Xeris Pharmaceuticals Inc can leverage various opportunities to strengthen its position and drive growth:

  • Expanding market demand: The growing need for innovative pharmaceutical solutions and increasing healthcare expenditures create opportunities for Xeris Pharmaceuticals to introduce new products and expand its market share.
  • Global expansion: The company can explore international markets to broaden its customer base and reduce dependency on domestic sales. Strategic partnerships with international distributors can facilitate market entry and expansion.
  • Research advancements: Continuous advancements in medical research and technology present opportunities for Xeris Pharmaceuticals to develop novel drugs and therapies that address unmet medical needs.

Threats

Xeris Pharmaceuticals Inc should be mindful of the following threats that could impact its business:

  • Intense competition: The pharmaceutical industry is highly competitive, with numerous companies vying for market share. Xeris Pharmaceuticals faces the risk of competitors introducing similar or more advanced products.
  • Regulatory challenges: Stringent regulations and requirements imposed by governing bodies can delay product launches and increase compliance costs. Non-compliance may lead to product recalls or legal issues.
  • Intellectual property infringement: Xeris Pharmaceuticals' proprietary formulation technology and patents may be subject to infringement by competitors, leading to loss of exclusivity and potential revenue decline.

Xeris Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Xeris Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Xeris Pharmaceuticals shares outstanding

The number of shares was Xeris Pharmaceuticals in 2023 — This indicates how many shares 137.675 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Xeris Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Xeris Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Xeris Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Xeris Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Xeris Pharmaceuticals.

Xeris Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.11 -0.1  (8.09 %)2024 Q2
3/31/2024-0.12 -0.14  (-17.65 %)2024 Q1
12/31/2023-0.1 -0.1  (0 %)2023 Q4
9/30/2023-0.12 -0.09  (23.92 %)2023 Q3
6/30/2023-0.13 -0.14  (-7.61 %)2023 Q2
3/31/2023-0.17 -0.12  (29.78 %)2023 Q1
12/31/2022-0.16 -0.1  (37.77 %)2022 Q4
9/30/2022-0.17 -0.16  (4.93 %)2022 Q3
6/30/2022-0.23 -0.19  (19.01 %)2022 Q2
3/31/2022-0.26 -0.25  (3.51 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Xeris Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

63/ 100

🌱 Environment

66

👫 Social

80

🏛️ Governance

43

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Xeris Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
6.04 % BlackRock Institutional Trust Company, N.A.8,995,574593,70212/31/2023
4.76 % The Vanguard Group, Inc.7,086,34560,18112/31/2023
3.98 % Stonepine Capital Management, LLC5,937,00021,62812/31/2023
3.79 % Caxton Associates LP5,641,920012/31/2023
2.58 % BioImpact Capital LLC3,847,232-140,73512/31/2023
2.38 % Rosalind Advisors, Inc.3,543,6853,543,68512/31/2023
1.94 % Geode Capital Management, L.L.C.2,892,077118,78412/31/2023
1.83 % State Street Global Advisors (US)2,724,126154,00412/31/2023
1.68 % Medical Strategy GmbH2,505,175-220,23112/31/2023
1.59 % Edick (Paul Raymond)2,373,2111,500,0001/31/2024
1
2
3
4
5
...
10

Xeris Pharmaceuticals Executives and Management Board

Mr. Paul Edick67
Xeris Pharmaceuticals Chairman of the Board, Chief Executive Officer (since 2018)
Compensation 2.81 M
Mr. John Shannon61
Xeris Pharmaceuticals President, Chief Operating Officer
Compensation 1.53 M
Ms. Beth Hecht59
Xeris Pharmaceuticals Chief Legal Officer, Corporate Secretary (since 2021)
Compensation 1.27 M
Mr. John Schmid60
Xeris Pharmaceuticals Lead Independent Director
Compensation 162,235
Dr. BJ Bormann64
Xeris Pharmaceuticals Independent Director
Compensation 127,235
1
2
3

Most common questions regarding Xeris Pharmaceuticals

What values and corporate philosophy does Xeris Pharmaceuticals represent?

Xeris Pharmaceuticals Inc represents a commitment to innovation, patient care, and delivering life-changing solutions in the pharmaceutical industry. With a focus on developing therapies for patients with complex and chronic conditions, Xeris Pharmaceuticals prioritizes patient safety and therapeutic effectiveness. The company embraces a patient-centered approach by developing products that address unmet medical needs and improve patients' quality of life. Xeris Pharmaceuticals also values collaboration with healthcare professionals, fostering partnerships to advance research and development. By staying at the forefront of pharmaceutical innovation, Xeris Pharmaceuticals aims to provide accessible and effective treatments for patients worldwide.

In which countries and regions is Xeris Pharmaceuticals primarily present?

Xeris Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Xeris Pharmaceuticals achieved?

Xeris Pharmaceuticals Inc has achieved several significant milestones since its establishment. The company successfully launched its first commercial product, Gvoke® as a treatment for severe hypoglycemia in 2019. Xeris Pharmaceuticals also received FDA approval for Ogluo™, a ready-to-use liquid glucagon product, in 2020. Furthermore, the company has made progress in developing its proprietary XeriSol™ and XeriJect™ formulations, which aim to improve the delivery of known pharmaceutical compounds. Xeris Pharmaceuticals continues to advance its pipeline, focusing on developing innovative solutions for various acute and chronic diseases.

What is the history and background of the company Xeris Pharmaceuticals?

Xeris Pharmaceuticals Inc is a renowned pharmaceutical company specializing in developing innovative therapies for various medical conditions. Established in 2005, Xeris has emerged as a leader in the biopharmaceutical industry, dedicated to providing novel treatment options. The company's mission revolves around addressing unmet medical needs by developing solutions that enhance patient outcomes and improve quality of life. Xeris Pharmaceuticals Inc has built a strong reputation for its groundbreaking research and development initiatives, collaborating with experts and organizations worldwide. With a focus on cutting-edge technologies and a commitment to advancing healthcare, Xeris Pharmaceuticals Inc continues to make significant strides in the pharmaceutical landscape.

Who are the main competitors of Xeris Pharmaceuticals in the market?

The main competitors of Xeris Pharmaceuticals Inc in the market are other pharmaceutical companies that operate in the same therapeutic areas. Some notable competitors include AstraZeneca, Eli Lilly and Company, Novo Nordisk, and Sanofi. Xeris Pharmaceuticals Inc competes with these companies in developing innovative solutions for diabetes and other endocrine disorders. With its focus on novel delivery technologies, Xeris Pharmaceuticals Inc aims to differentiate itself from its competitors and provide value to patients and healthcare providers.

In which industries is Xeris Pharmaceuticals primarily active?

Xeris Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Xeris Pharmaceuticals?

Xeris Pharmaceuticals Inc. is a pharmaceutical company specializing in developing and commercializing ready-to-use injectable and infusible drug formulations. Their innovative technology allows the development of products that can be administered without reconstitution or dilution. Xeris Pharmaceuticals Inc. aims to improve patient care by providing convenient, safe, and effective treatments for various medical conditions. With their focus on developing stable and room-temperature stable formulations, the company aims to simplify drug administration and enhance patient compliance. Xeris Pharmaceuticals Inc. is committed to advancing its pipeline and collaborating with partners to bring cutting-edge therapies to market.

What is the P/E ratio of Xeris Pharmaceuticals 2024?

The Xeris Pharmaceuticals P/E ratio is -5.71.

What is the P/S ratio of Xeris Pharmaceuticals 2024?

The Xeris Pharmaceuticals P/S ratio is 1.75.

What is the AlleAktien quality score of Xeris Pharmaceuticals?

The AlleAktien quality score for Xeris Pharmaceuticals is 4/10.

What is the revenue of Xeris Pharmaceuticals 2024?

The expected Xeris Pharmaceuticals revenue is 197.27 M USD.

How high is the profit of Xeris Pharmaceuticals 2024?

The expected Xeris Pharmaceuticals profit is -60.54 M USD.

What is the business model of Xeris Pharmaceuticals

Xeris Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of innovative therapies for patients with diabetes and endocrine disorders. Founded in 2005 in Austin, Texas, the company actively works on developing drugs that aim to make insulin therapy more effective and safer. Xeris Pharmaceuticals Inc's business model is based on the development and distribution of novel medications. The company is divided into several divisions, including diabetology, endocrinology, and pediatrics. Xeris' products are primarily targeted towards the US market, where there is a growing demand for innovative diabetes therapies. The company's flagship product is the glucagon rescue pen, a medication used for hypoglycemia. Hypoglycemia occurs when a diabetic patient's blood sugar level is too low. The glucagon rescue pen is used in emergencies to quickly and effectively help the individual. The medication is easy to use and does not require specialized knowledge for application. Another important product from Xeris Pharmaceuticals Inc is the G-Pen Mini, specifically designed for children with diabetes. The G-Pen Mini is the first glucagon rescue pen specifically designed for children, simplifying the application and dosage of glucagon in emergencies. In addition to these products, Xeris Pharmaceuticals Inc is also working on the development of novel insulin products. Insulin is a hormone needed by diabetics to control their blood sugar levels. Xeris has developed a new formulation of insulin that will be launched in the form of a self-injectable pen, making it easier for diabetics to dose their insulin. Another area of focus for Xeris Pharmaceuticals Inc is researching medications for excessive adrenaline production in children. Adrenaline is a hormone released by the body to cope with stressful situations. However, some children with endocrine disorders produce too much adrenaline, which can lead to serious health problems. Xeris is actively working on developing a new medication to treat this condition. Xeris Pharmaceuticals Inc is an innovative company that constantly focuses on the development of new therapies. With a dedicated research department and a strong team of leaders, Xeris positions itself as a leader in diabetes therapy. Through consistent product development and marketing, Xeris Pharmaceuticals Inc will continue to be successful with its proven business model.

What is the Xeris Pharmaceuticals dividend?

Xeris Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Xeris Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Xeris Pharmaceuticals or the company does not pay out a dividend.

What is the Xeris Pharmaceuticals ISIN?

The ISIN of Xeris Pharmaceuticals is US98422L1070.

What is the Xeris Pharmaceuticals WKN?

The WKN of Xeris Pharmaceuticals is A2JPE9.

What is the Xeris Pharmaceuticals ticker?

The ticker of Xeris Pharmaceuticals is XERS.

How much dividend does Xeris Pharmaceuticals pay?

Over the past 12 months, Xeris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xeris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Xeris Pharmaceuticals?

The current dividend yield of Xeris Pharmaceuticals is .

When does Xeris Pharmaceuticals pay dividends?

Xeris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xeris Pharmaceuticals?

Xeris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Xeris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xeris Pharmaceuticals located?

Xeris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xeris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xeris Pharmaceuticals from 9/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did Xeris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of Xeris Pharmaceuticals in the year 2023?

In the year 2023, Xeris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Xeris Pharmaceuticals pay out the dividend?

The dividends of Xeris Pharmaceuticals are distributed in USD.

All fundamentals about Xeris Pharmaceuticals

Our stock analysis for Xeris Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xeris Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.